Neurol Case Rep | Volume 6, Issue 1 | Case Report | Open Access
Tedjasukmana R1*, Sudoyo AW2 and Widjaja P3
1Department of Neurology, Medistra Hospital, Krida Wacana Christian University, Indonesia 2Department of Internal Medicine, Medistra Hospital, University of Indonesia, Indonesia 3Deparment of Radiology, Medistra Hospital, Jakarta, Indonesia
*Correspondance to: Rimawati Tedjasukmana
Fulltext PDFBackground: Oxaliplatin is a chemotherapeutic agent that consists of a platinum compound that inhibits DNA synthesis. Widely used for various cancers, this drug can have neurological, gastrointestinal or hematological side effects. The most common neurological adverse effect of this drug is peripheral sensory neuropathy. Although quite rare, there have been several reports of seizures associated with the chemotherapy-related toxicity of oxaliplatin. Generally, these patients showed concomitant blood pressure elevation and Posterior Reversible Encephalopathy Syndrome (PRES) on Brain Magnetic Resonance Imaging (MRI). However, there was a report of one patient who did not show evidence of PRES. Case Report: We report a second case of oxaliplatin-induced status epilepticus in the absence of PRES. The patient was a 74-year-old Indonesian woman diagnosed with colorectal cancer. In this patient seizures occurred a few days after the first cycle of treatment. Her blood pressure remained normal and her brain MRI showed no sign of metastasis or PRES. She became conscious with no neurological sequelae 4 days after her seizures. Conclusion: These cases challenge the notion that oxaliplatin-induced seizures are caused by PRES. Perhaps there are other unknown mechanisms involved. The risk of seizures induced by oxaliplatin is low. However, physicians need to be aware of this risk and inform their patients accordingly.
Chemotherapy-related toxicity; Oxaliplatin; Posterior reversible encephalopathy syndrome; Seizures
Tedjasukmana R, Sudoyo AW, Widjaja P. Oxaliplatin-Induced Status Epilepticus in the Absence of Posterior Reversible Encephalopathy Syndrome: A Case Report. Neurol Case Rep. 2023;6(1):1036..